- Home
- AISP vs ALLK Comparison
AISP vs ALLK Comparison
Compare AISP & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AISP
- ALLK
- Stock Information
- Founded
- AISP 2006
- ALLK 2012
- Country
- AISP United States
- ALLK United States
- Employees
- AISP N/A
- ALLK N/A
- Industry
- AISP Blank Checks
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- AISP Finance
- ALLK Health Care
- Exchange
- AISP Nasdaq
- ALLK Nasdaq
- Market Cap
- AISP 62.6M
- ALLK 58.0M
- IPO Year
- AISP N/A
- ALLK 2018
- Fundamental
- Price
- AISP $2.85
- ALLK $1.16
- Analyst Decision
- AISP Strong Buy
- ALLK Hold
- Analyst Count
- AISP 2
- ALLK 5
- Target Price
- AISP $9.00
- ALLK $1.67
- AVG Volume (30 Days)
- AISP 1.2M
- ALLK 1.3M
- Earning Date
- AISP 11-14-2024
- ALLK 11-06-2024
- Dividend Yield
- AISP N/A
- ALLK N/A
- EPS Growth
- AISP N/A
- ALLK N/A
- EPS
- AISP 0.73
- ALLK N/A
- Revenue
- AISP $24,050,308.00
- ALLK N/A
- Revenue This Year
- AISP $111.47
- ALLK N/A
- Revenue Next Year
- AISP $32.94
- ALLK N/A
- P/E Ratio
- AISP $3.89
- ALLK N/A
- Revenue Growth
- AISP 148.46
- ALLK N/A
- 52 Week Low
- AISP $1.34
- ALLK $0.54
- 52 Week High
- AISP $14.32
- ALLK $3.41
- Technical
- Relative Strength Index (RSI)
- AISP 55.37
- ALLK 51.18
- Support Level
- AISP $2.08
- ALLK $1.29
- Resistance Level
- AISP $4.40
- ALLK $1.56
- Average True Range (ATR)
- AISP 0.40
- ALLK 0.14
- MACD
- AISP 0.15
- ALLK -0.03
- Stochastic Oscillator
- AISP 38.00
- ALLK 14.89
About AISP Airship AI Holdings Inc.
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where they need it, using a highly secure permission-based architecture.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.